Pfizer won't launch its second Remicade biosimilar in U.S.
Paliperidone and Clindamycin Recalls
Sodium Bicarbonate Injections RecalledThe recall is a major setback in the ongoing sodium bicarbonate shortage.
The 4 most problematic drug shortagesDrug shortages are significant public health threats. They can delay, or even deny, critical care for patients. Here are the four drugs in shortage that are among the most problematic.
New forum expands access to biosimilarsThe non-profit Biosimilars Forum was launched in May 2015 to offer credible, sustained, and unbiased education about biosimilars. The founding members of the Biosimilars Forum represent the majority of companies with the most significant US biosimilars development portfolios.
Patent litigation could hold up biosimilarsEleven of the most promising biosimilars will create an estimated $250 billion in savings for U.S. payers, according to pharmacy benefits manager Express Scripts.
Non-opioid painkiller gets FDA approvalFDA's approval of a new non-opioid painkiller injection expected to help in the fight against prescription painkiller abuse.
Naloxone price increases may threaten public safetyA price increase for a popular form of the medication, naloxone, threatens the ability of non-profit programs and organizations, including police departments around the country, to provide a medical antidote for drug overdoses.
Compounding may not be best option during saline shortageThe shortage of saline solution among hospitals is ongoing and doesn’t appear to be resolving anytime soon, according to a quality executive with the American Society of Health-System Pharmacists (ASHP). In addition, safety concerns make it prohibitive for hospitals to compound their own solutions.
Hospira scores temporary win in lawsuit versus FDAPrecedex, dexmedetomidine hydrochloride, is approved to sedate patients with breathing tubes in an intensive-care setting, as well as patients without breathing tubes before and during surgeries and other procedures. Hospira’s patent that covers the use of Precedex in an intensive-care setting in due to expire in 2019, however other patents have already expired. On Monday, the FDA approved the sale of generic copies of the drug as long as the companies leave out information from the prescribing labels about uses that are covered under Hospira’s patent, including “intensive-care unit sedation.”